BMT is curative in almost 75% of children affected by severe primary immunodeficiencies (PIDs). Recently, the chance of cure has increased thanks to the availability of matched unrelated donors (MUDs). Nevertheless, besides the conventional indications to BMT (profound or absent T-cell function, profound or absent natural killer function, known syndromes with T-cell deficiencies), indications to BMT for PIDs affecting the quality of life or having an expectation of life that does not exceed the third-fourth decade remain unclear. Infact, if it is evident that the survival rate in an infant grafted for a PID with a MUD is expected to be more than 80%, alternative treatments such as gene therapy are now available.
Introduction
BMT is the treatment of choice for severe primary immunodeficiencies (PIDs; SCID), for syndromes associated with immunodeficiencies such as Wiskott-Aldrich syndrome and for most forms of congenital defects of neutrophil function. Indications for BMT are constantly updated as BMT results and techniques utilized in most cases offer more than 90% EFS. Nevertheless, since PIDs are congenital diseases, is uneven that a child affected would have a matched family donor. In our experience, the estimate probability to have a matched family donor does not exceed 5%. Therefore, since 1990, in our center for BMT 'Monica e Luca Folonari', Italian referent center for BMT treatment for PIDs, the procedure in most cases is realized by alternative donors. The Center of Brescia registers the Italian cases also in the European SCETIDE registry (Figure 1 ). 1, 2 Up to the year 2000, BMT was realized from the mother or the father after T-cell depletion of the marrow; from 1986 to 1996, and by the monoclonal antibody 
Indications for BMT
Indications for BMT in PID patients are susceptible to change with time as alternative treatments are available. One example is chronic granulomatous disease; gene therapy, where the role of BMT still now is discussed or of SCID, due to adenosine deaminase deficiency, where BMT without conditioning from matched familial donor engrafts, but immunological reconstitution is protracted. On the other hand, the increasing number of BMT from volunteer donors that requires pre transplant conditioning, substitutive polyethylene glycol-adenosine deaminase enzymatic therapy (the missing enzyme associated with polyethylene glycol) and gene therapy are promising alternative to the conventional BMT approach. BMT remains the treatment of choice for adhesion proteins deficiencies (type 1), of integrins expression (leukocyte adhesion protein deficiency), while in partial forms (type 2), the decision to go to BMT or to control the diseases by drugs depends on the clinical history and the clinical conditions of the affected child. Wiskott-Aldrich syndrome is another example that presents with a range of clinical forms: BMT has to be performed in severely affected cases, as survival is uneven in these patients, whereas in isolated forms of X-linked thrombocytopenia (congenital thrombocytopenia), indications for BMT are discussed ( Figure 3) .
Recently, a new cohort of diseases have compulsory BMT indications: diseases characterized by defective natural killer activity (virus-associated syndromes, Chediak-Higashi syndrome, Duncan syndrom and etc.) ( Table 1) .
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Clinical results of Allo-SCT Since 1990, 137 children affected by PID underwent SCT in our unit, SCID in 82 children, combined immunodeficiency in 19, Wiskott-Aldrich syndrome in 22, natural killer defect (in 9 and phagocyte deficiency in 5) (Figure 4) .
Results of BMT were analyzed evaluating the impact of the type of the disease on EFS dividing the children in two cohorts: children affected by SCID and children affected by other PID. This analysis is based on the graft resistance difference existing among the two groups of patients. In fact, while SCID-affected children engraft more easily even stem cells originating from partially matched donors, as the profound T-cell defect allows engraftment, children affected by other immunodeficiencies often requires intensive pre transplant conditioning regimens. If we consider the 82 children affected by SCID, 15 had a matched family donor, 2 had phenoidentical familial donors, 47 had partially matched familial, 18 had MUD. Survival of children grafted with an MUD exceeds 80%, while children grafted with partially matched family donors is 55% ( Figure 5 ). [8] [9] [10] As far as children affected by non-SCID PID are concerned, patients with a matched family donor or matched unrelated have a survival that exceeds 90%. On the other hand, haploidentical transplant offers a survival that does not exceed 50% (Figure 6 ). In five children affected by SCID, BMT has been realized prenatally, after prenatal diagnosis, utilizing one of the parents as donor. In all cases, the clinical results of the procedure was comparable to the results of postnatal transplants. 92.9% Figure 6 Event-free survival in 55 children affected by PID non-SCID who underwent BMT in Brescia.
pediatrics. Despite the fact that anyhow PID are orphan disease, the only chance to cure them depends on an early diagnosis, often in the neonatal period. Therefore, it is critical to circulate as much as we can the information on first symptoms, on clinical findings, on laboratory tests that characterize these diseases and allow a prompt and accurate diagnosis. Furthermore, PIDs are an heterogeneous group of different diseases, each with peculiar molecular, immunological and clinical features, and therefore, often with the need of a 'tailored' therapeutic approach.
